Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses

No abstract is available for this paper.

• Publication year

  2010

• Venue

  British Journal of Haematology

• Publication date

  2010-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2141.2010.08107.xPMID 20230404
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.

  2011cited by this paper
• Anthracycline-Associated Cardiotoxicity in Survivors of Childhood Cancer

  2011cited by this paper
• Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.

  2010cited by this paper
• Isolated central nervous system relapse in acute promyelocytic leukemia (APL)—response

  2009cited by this paper
• Precursor T-Lymphoblastic Lymphoma as a Secondary Malignancy in a Young Patient after Successful Treatment of Acute Promyelocytic Leukemia

  2009cited by this paper
• Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

  2009cited by this paper
• Acute promyelocytic leukemia in childhood

  2009cited by this paper
• High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG

  2009cited by this paper
• Pharmacologic Prevention of Anthracycline-Induced Cardiomyopathy

  2009cited by this paper
• Central nervous system involvement in relapsed acute promyelocytic leukemia

  2009cited by this paper
• Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.

  2009cited by this paper
• Review Articles (434 articles)

  2008cited by this paper
• Acute promyelocytic leukemia: from highly fatal to highly curable.

  2008cited by this paper
• Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group.

  2008cited by this paper
• Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML

  2007cited by this paper
• Anthracycline associated cardiotoxicity in survivors of childhood cancer

  2007cited by this paper
• Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.

  2006cited by this paper
• Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.

  2006cited by this paper
• Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.

  2006cited by this paper
• Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence.

  2005cited by this paper
• Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group.

  2005cited by this paper
• GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children.

  2005influential reference
• Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia.

  2005influential reference
• Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials

  2005cited by this paper
• Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience

  2004cited by this paper
• Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.

  2004cited by this paper
• All-trans retinoic acid As 2 O 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia

  2004cited by this paper
• All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.

  2004cited by this paper
• Arsenic trioxide in the treatment of acute promyelocytic leukemia

  2003cited by this paper
• The Statistical Analysis of Failure Time Data

  2003cited by this paper
• [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].

  2002cited by this paper
• All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.

  2002cited by this paper
• Second malignancy after treatment of acute promyelocytic leukemia : experience of GIMEMA trials

  2002cited by this paper
• Second malignancy after treatment of acute promyelocytic leukemia: experience of GIMEMA trials. Gruppo Italiano Malattie Ematologiche dell'Adulto.

  2002cited by this paper
• The Statistical Analysis of Failure Time Data: Kalbfleisch/The Statistical

  2002cited by this paper
• Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem.

  2002cited by this paper
• Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children

  2001cited by this paper
• Arsenic trioxide for the treatment of acute promyelocytic leukemia.

  2001influential reference
• Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study.

  2001cited by this paper
• United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.

  2001cited by this paper
• Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93

  2001cited by this paper
• From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 23, 2013. For personal use

  2000cited by this paper
• Cardiac Toxicity after Anthracycline Chemotherapy in Childhood

  2000cited by this paper
• Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia

  2000cited by this paper
• Treatment‐related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council Acute Myeloid Leukaemia Trial (MRC AML10)

  1999cited by this paper
• A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.

  1999cited by this paper
• A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group.

  1999cited by this paper
• Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto.

  1999cited by this paper
• Definition of a standard‐risk group in children with AML

  1999cited by this paper
• A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia

  1998cited by this paper
• High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia.

  1996cited by this paper
• High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia.

  1996cited by this paper
• Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group.

  1993cited by this paper
• Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group

  1993cited by this paper
• Microgranular variant of acute promyelocytic leukemia in children.

  1992cited by this paper
• Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO)

  1991cited by this paper
• Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.

  1990cited by this paper
• Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group.

  1985cited by this paper
• Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

  1985cited by this paper

• Chemotherapy-free treatment for acute promyelocytic leukemia: the pediatric view of a revolutionary tale

  2023cites this paper
• Has Hematopoietic Stem Cell Transplantation a Role in the Treatment of Children and Adolescents with Acute Promyelocytic Leukemia?

  2022cites this paper
• High-throughput drug screening reveals Pyrvinium pamoate as effective candidate against pediatric MLL-rearranged acute myeloid leukemia

  2021cites this paper
• Forecasting essential childhood cancer drug need: An innovative model‐based approach

  2021cites this paper
• Clinical Characteristics and Treatment Outcomes of Childhood Acute Promyelocytic Leukemia in Korea: A Nationwide Multicenter Retrospective Study by Korean Pediatric Oncology Study Group

  2021cites this paper
• An Outcome Analysis of Childhood Acute Promyelocytic Leukemia Treated with Atra and Arsenic Trioxide, and Limited Dose Anthracycline

  2021cites this paper
• Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients — a 25‐year Italian experience

  2021cites this paper
• Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients — a 25-year Italian experience

  2021cites this paper
• Long-term follow-up of children with acute promyelocytic leukemia treated with Beijing Children’s Hospital APL 2005 protocol (BCH-APL 2005)

  2019cites this paper
• Akute Promyelozyten-Leukämie: Neue Behandlungsstrategien mit ATRA und ATO – AML-BFM-Empfehlungen

  2018cites this paper
• APL in Children

  2018cites this paper
• Management of patients with acute promyelocytic leukemia

  2018cites this paper
• 10 Pediatric Acute Myeloid Leukemia

  2018cites this paper
• Risk-adapted treatment of acute promyelocytic leukemia : results from International Consortium for Childhood APL Running title : risk-adapted therapy for childhood APL

  2018cites this paper
• Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL.

  2018cites this paper
• Acute Promyelocytic Leukemia in Children: A Single Centre Experience from Turkey

  2018cites this paper
• Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance)

  2018cites this paper
• First experience of the AML‐Berlin‐Frankfurt‐Münster group in pediatric patients with standard‐risk acute promyelocytic leukemia treated with arsenic trioxide and all‐trans retinoid acid

  2017cites this paper
• Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy

  2017cites this paper
• Thiosemicarbazone derivatives, thiazolyl hydrazones, effectively inhibit leukemic tumor cell growth: Down-regulation of ribonucleotide reductase activity and synergism with arabinofuranosylcytosine.

  2017cites this paper
• Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives

  2017cites this paper
• Studies on Arsenic and Human Health

  2017cites this paper
• Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives

  2017cites this paper
• Acute myeloid leukaemia ( AML )-Brief information 1

  2017cites this paper
• Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives

  2017cites this paper
• High event‐free survival rate with minimum‐dose‐anthracycline treatment in childhood acute promyelocytic leukaemia: a nationwide prospective study by the Japanese Paediatric Leukaemia/Lymphoma Study Group

  2016cites this paper
• Cardiotoxicity of anthracycline therapy: current perspectives

  2016cites this paper
• Introduction: Childhood Leukemia

  2016cites this paper
• Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel

  2016cites this paper
• Acute myeloid leukemia in children: Current status and future directions

  2016cites this paper
• Global characteristics of childhood acute promyelocytic leukemia.

  2015cites this paper
• How I treat children and adolescents with acute promyelocytic leukaemia

  2014influential citation
• Induction mortality, ATRA administration, and resource utilization in a nationally representative cohort of children with acute promyelocytic leukemia in the United States from 1999 to 2009

  2014cites this paper
• Acute Promyelocytic Leukemia (APL): Comparison Between Children and Adults

  2014cites this paper
• Treatment of paediatric APL: how does the therapeutic approach differ from adults?

  2014cites this paper
• Development of treatment and clinical results in childhood AML in Austria (1993–2013)

  2014cites this paper
• [Treatment of adult patients with acute promyelocytic leukemia according to the AIDA protocol].

  2013cites this paper
• All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene

  2013cites this paper
• Development of treatment and clinical results in childhood acute myeloid leukemia in the Czech Republic

  2013cites this paper
• Development of a Curative Treatment within the AML-BFM Studies

  2013cites this paper
• adolescents: recommendations from an international expert panel Diagnosis and management of acute myeloid leukemia in children and

  2013cites this paper
• Retrospective analysis of 119 cases of pediatric acute promyelocytic leukemia: Comparisons of four treatment regimes.

  2012cites this paper
• Retinoids in Pediatric Onco-Hematology: the Model of Acute Promyelocytic Leukemia and Neuroblastoma

  2012cites this paper
• Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report

  2012cites this paper
• Subclinical anthracycline cardiotoxicity in patients with acute promyelocytic leukemia in long-term remission after the AIDA protocol.

  2012cites this paper
• Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel.

  2012cites this paper
• Quantification of PML/RARa transcript after induction predicts outcome in children with acute promyelocytic leukemia

  2012cites this paper
• All-trans retinoic acid in the treatment of pediatric acute promyelocytic leukemia

  2012cites this paper
• Pediatric acute myeloid leukemia

  2012cites this paper
• Pediatric Acute Myeloid Leukemia

  2011cites this paper
• Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia

  2011cites this paper
• From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia.

  2011cites this paper
• New Targets and Targeted Drugs for the Treatment of Cancer: An Outlook to Pediatric Oncology

  2011cites this paper
• n Der Schmerz als Alarmsystem

  2011cites this paper